Skip to Content logo

News Release

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, M.D., MPH, MBA will join the company as Chief Medical Officer and Anne-Marie (Annie) Martin, Ph.D., has been appointed to the Company’s Board of Directors. Dr. Jones joins Cullinan Oncology from Bristol Myers Squibb where he held positions of increasing responsibility in oncology clinical development, most recently as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases. Dr. Martin brings to Cullinan Oncology over 25 years of translational medicine and clinical research expertise, and is currently Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline.

“The appointments of Dr. Jeff Jones as Chief Medical Officer and of Dr. Annie Martin to our Board of Directors expands our expertise within the oncology space and brings diverse perspectives to our leadership team,” said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology. “With the continued advancement of our pipeline, we are excited to welcome two industry experts who will help us to optimize our upcoming opportunities in late-stage drug development across multiple modalities and indications. Dr. Jones’s successful academic tenure and deep expertise in oncology drug development will be vital to our mission to create new standards-of-care for patients with cancer. Similarly, Dr. Martin is an internationally trained scientist, and senior pharmaceutical executive with deep drug development and translational medicine experience who will bring added oncology expertise and valued perspective to our Board of Directors.”   
Most recently, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases, where he led the development and lifecycle management strategy for Reblozyl®, across both benign and malignant hematology indications. In prior roles, Dr. Jones led disease area, clinical and business development strategy for B-cell malignancies across a diverse portfolio of small and large molecules from early-to-late-stage development. Dr. Jones received his M.D. from University of Michigan Medical School in Ann Arbor, Michigan and completed his residency in internal medicine at McGill University Faculty of Medicine in Montreal and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, Texas. Dr. Jones also holds an M.B.A. from The Ohio State University Fisher College of Business and an M.P.H. from the University of Texas School of Public Health.

Dr. Martin has held numerous roles at GlaxoSmithKline, Novartis, and Adaptimmune, spanning leadership positions in precision medicine, translational medicine and clinical research. Her distinguished career has also included a number of university appointments inclusive of teaching and research positions. She received her undergraduate degree in biomedical sciences from Sheffield Hallam University, Sheffield, UK and a Ph.D. in Immunogenetics from MCP-Hahnemann University in Philadelphia.  

“I am thrilled to welcome Dr. Anne-Marie Martin to the Cullinan Oncology Board of Directors, where she will bring her experience and vision for oncology product development,” said Tony Rosenberg, Chairman of the Board of Directors of Cullinan Oncology. “Dr. Martin has a proven and successful track record as an internationally trained scientist, thought leader and senior pharmaceutical executive in drug development and translational medicine across numerous therapeutic areas, all of which will be extremely beneficial to the Cullinan Oncology team both now and in the future.”  
About Cullinan Oncology  
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to patients with cancer. The Company’s strategy is to source innovation through both internal discovery efforts and external collaborations, focusing on advanced stage assets with novel technology platforms and differentiated mechanisms. Learn more about Cullinan Oncology at  
Forward-Looking Statements  
This press release contains forward-looking statements of Cullinan Oncology, Inc. (“Cullinan,” “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan’s beliefs and expectations regarding our preclinical and clinical development plans, clinical trial designs, clinical and therapeutic potential, and strategy of our product candidates. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our product candidates; risks related to the impact of COVID-19 affecting countries or regions in which we have operations or do business, including potential negative impacts on our employees, customers, supply chain and production as well as global economies and financial markets; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.    


Investor Relations  
Lee Roth / Dr. Grace Kim  
+1 212.213.0006 /   
Jeffrey Trigilio  
+1 617.410.4650   
Rose Weldon 
+1 215.801.7644